Format

Send to

Choose Destination
Annu Rev Pharmacol Toxicol. 2014;54:185-203. doi: 10.1146/annurev-pharmtox-011613-135957. Epub 2013 Oct 2.

microRNA therapeutics in cardiovascular disease models.

Author information

1
Institute of Molecular and Translational Therapeutic Strategies (IMTTS).

Abstract

Cardiovascular diseases are a major cause of human morbidity and mortality, posing a high socioeconomic burden on the health sector worldwide. microRNAs (miRNAs) constitute a new class of unique molecular regulators involved in the pathophysiology of a wide range of disorders. Studies in the past decade have identified miRNA signatures of various cardiovascular disorders and successfully validated miRNA-based therapeutic options in various small and a few large experimental cardiovascular disease models. In these models, researchers manipulate the expression of miRNAs and downstream signaling cascades, aiming to prevent and cure cardiovascular disease. Here, we review and discuss the recent reports on the in vivo use of miRNA animal models and miRNA therapeutic development as well as provide an outlook for clinical applications in the near future.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center